Medicare, commercial payer, PBM, and formulary-policy moves that shape launch curves and gross-to-net.
Six FDA-approved biosimilars now compete with Eylea (aflibercept) in ophthalmology, two with interchangeable designation. This reference-product dossier maps every...
Six FDA-approved biosimilars now compete with Herceptin (trastuzumab) in oncology. This reference-product dossier maps every approved product, payer formulary...
The Inflation Reduction Act eliminated the Part D donut hole, capped out-of-pocket drug spending at $2,100 for 2026, and restructured cost-sharing across three phases....
Ten FDA-approved biosimilars now compete with Humira (adalimumab). This reference-product dossier maps every approved product, interchangeability status, payer adoption,...
Mounjaro and Zepbound contain the same active ingredient, tirzepatide, but carry different FDA indications, different coverage pathways, and different payer rules. This...
Humira (adalimumab) was once the world's best-selling drug, but its access landscape has transformed. With ten biosimilars now FDA-approved and all three major PBMs...
Rinvoq (upadacitinib) and Humira (adalimumab) represent two fundamentally different approaches to treating rheumatoid arthritis, psoriatic arthritis, and other...
Skyrizi (risankizumab) and Stelara (ustekinumab) are both IL-23 pathway inhibitors used in plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis...
